D-Coate

Quick links to important sections

D-Coate

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of D-Coate

Property Description
Active Ingredients Dextromethorphan Hydrobromide, Guaifenesin, Terpin
Form Oral Liquid (syrup, elixir) or Tablets/Capsules
Pharmacological Class Antitussive and Expectorant
Common Use Symptomatic relief of cough and chest congestion
Origin Primarily Synthetic (Dextromethorphan, Guaifenesin)

What Type of Combination Medication is D-Coate?

D-Coate is an oral combination product designed to address multiple symptoms simultaneously, distinguishing it as a comprehensive approach to respiratory ailments. It is structurally classified as both an antitussive (cough suppressant) and an expectorant (mucus thinner) due to the dual functions of its active ingredients. This medication is typically administered through the oral route and is available in common dosage forms such as liquid or solid tablets.

Dextromethorphan is a cough suppressant that acts centrally. In this capacity, the medicine helps to quiet the signals that trigger the urge to cough.

D-Coate's Active Ingredients and General Purpose

The composition of D-Coate relies on three principal active ingredients: Dextromethorphan Hydrobromide, Guaifenesin, and Terpin. This specific three-component formulation is a key differentiating factor, providing a broader spectrum of action compared to common two-ingredient combinations. Dextromethorphan Hydrobromide is the synthetic agent providing the antitussive action. Guaifenesin and Terpin (often used as the derived form Terpin Hydrate) function as expectorants, which increase the volume of fluid in the respiratory tract.

Guaifenesin aids in making bronchial secretions thinner, facilitating their removal. The overall general purpose of D-Coate is to provide symptomatic relief for both the non-productive cough and the heavy, difficult-to-clear chest congestion typically seen during the common cold or bronchitis.

Regulatory References

  1. Dextromethorphan: MedlinePlus Drug Information
  2. Guaifenesin: MedlinePlus Drug Information

What side effects are possible with D-Coate?

Possible Side Effects and Safety Information

The safety profile of D-Coate, an oral combination product containing Dextromethorphan, Guaifenesin, and Terpin, is structured according to regulatory classifications established by government health authorities.


System-Organ Classes and Frequency

Adverse reactions are formally grouped by the system-organ classes they affect. Regulatory documents classify common reactions as those frequently reported in clinical use, which often involve the Nervous System and Gastrointestinal Disorders

.

Commonly documented effects include dizziness, drowsiness, nausea, and vomiting. Less frequent or rare adverse reactions documented in the official safety profile include skin rash or urticaria (hives).


Serious Safety Considerations and Restrictions

Official labeling mandates specific constraints and highlights the potential for rare, serious events. A potentially life-threatening reaction known as Serotonin Syndrome is documented as a risk when Dextromethorphan is combined with Monoamine Oxidase Inhibitors (MAOIs); concurrent use is therefore an absolute regulatory contraindication.

Furthermore, the medication is not intended for use in individuals with chronic cough (such as that related to asthma or emphysema) or cough accompanied by excessive mucus accumulation. Use is also restricted to certain pediatric age limits, which vary by national label. Safety documents specify that if the cough persists for more than seven days, recurs, or is accompanied by fever, further use should be discontinued.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with D-Coate, primarily driven by the Dextromethorphan component, presents with documented Central Nervous System (CNS) manifestations. These signs include confusion, extreme drowsiness, nystagmus (involuntary eye movements), ataxia (lack of coordination), and agitation. Critical, life-threatening outcomes documented in regulatory sources include severe respiratory depression, seizures, and progression to coma. A potentially fatal complication, Serotonin Syndrome, is a documented risk, particularly when the product is taken concomitantly with other serotonergic medications.

Immediate medical attention must be sought for any suspected overdose. Government guidance mandates contacting emergency services or a certified Poison Help line immediately if severe symptoms, such as trouble breathing, loss of consciousness, or convulsions, occur. Management in a medical setting is officially described as symptomatic and supportive. While no specific antidote is known for the combination, Naloxone may be administered to reverse severe respiratory and CNS depression. Hospital monitoring and observation are required for all symptomatic patients. Official procedures advise against inducing vomiting (emesis). Regulatory notes advise caution regarding use in certain pediatric age groups due to documented risks in overdose scenarios.

Therapeutic Uses of D-Coate

D-Coate is applied in clinical settings that involve acute or unstable symptom patterns, providing short-term symptomatic assistance across key domains. It is relevant in situations where symptoms create noticeable physiological strain, offering supportive therapeutic benefit. The combination is utilized for the symptomatic management of the common cold, acute bronchitis, and flu-like illnesses.

The medication may assist in addressing symptom clusters related to persistent, non-productive cough and excessive mucus production alongside chest congestion. It is often used when symptoms intensify and supportive relief is needed to maintain functional stability. This dual action supports the patient during difficult episodes by easing distress.

“The primary goal is providing symptomatic relief that helps patients cope more steadily with difficult episodes, especially when multiple respiratory symptoms occur together.”

The core therapeutic domain is to address the intensity and impulse of the cough, supporting the clearance of mucus and bronchial secretions. This supportive function helps ease the overall symptom burden.


Quick Fact: Support for Acute Respiratory Symptoms

  • Dual Focus: Helps manage both the dry, irritating cough and heavy, congested chest often linked to upper respiratory infections.
  • Patient Benefit: Contributes to improved comfort during periods of heightened symptoms by assisting in the clearance of airways and reducing the frequency of coughing.

Regulatory References

  1. DailyMed Label for Dextromethorphan HBr and Guaifenesin

Eligibility and Restrictions for Use

Absolute Contraindications

D-Coate is absolutely prohibited for use in specific populations as defined by regulatory labeling:

  • Individuals currently taking, or who have discontinued within the last 14 days, a Monoamine Oxidase Inhibitor (MAOI).
  • Anyone with a known hypersensitivity to Dextromethorphan, Guaifenesin, Terpin, or any other ingredient in the specific formulation.
  • Patients with Phenylketonuria (PKU), if the formulation contains phenylalanine (e.g., from aspartame).

Eligibility and Restricted Use

D-Coate is approved for use in Adults and Children 12 years and older under standard labeled conditions. Regulatory agencies state that use is not recommended for Children under 12 years of age, and safety is not established for children under two years.

Consultation with a health professional is required before use for:

  • Patients with persistent or chronic cough (e.g., associated with asthma or emphysema).
  • Patients with cough accompanied by excessive phlegm or secretions.
  • Pregnant or breastfeeding individuals.
  • Patients with hepatic impairment (liver problems).

Older adults should use the medicine with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The product's use is contraindicated with certain other medicinal products, primarily Monoamine Oxidase Inhibitors (MAOIs). Official regulatory documents specify that D-Coate must not be taken concurrently with an MAOI, nor within 14 days of stopping MAOI therapy (e.g., phenelzine, selegiline). This restriction is necessary due to the risk of serious complications from the combined effects of these drug classes.

A second major area of interaction involves other serotonergic agents, such as Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs). Co-administration with these drugs requires caution, as they can enhance the effects of the active component. Additionally, certain medications are known to be potent CYP2D6 enzyme inhibitors (e.g., quinidine, fluoxetine, paroxetine). These inhibitors affect the metabolic breakdown of the drug, leading to significantly increased exposure, which may necessitate close patient monitoring. Always check labels for active ingredients to prevent inadvertent overdose from using multiple products that contain the same component.

Mechanism of Action

Central Modulation of Reflex Sensitivity

This mechanism centers on the drug's action as an agonist at the sigma1 receptor in the brainstem, which functions as a control center for the cough reflex arc. By engaging this central neural pathway, the drug raises the threshold required to trigger the involuntary, forceful exhalation. This receptor interaction results in a lowered central drive of the reflex, which modifies the frequency and intensity of the expulsion action.


Peripheral Regulation of Airway Fluid Dynamics

The drug also exerts a direct, peripheral effect on the secretory cells lining the respiratory tract. It acts as a modulator on these cells to increase the volume and decrease the viscosity (thickness) of the fluid layer lining the airways. This localized mechanical adjustment facilitates the easier movement and clearance of secretions from the respiratory tract by the mucociliary system, complementing the central action.

Dosage and Administration Information

Administration Guidelines for D-Coate

D-Coate (Dextromethorphan/Guaifenesin combination) is administered according to a short-term protocol. The medicine is exclusively for Oral use, available as an Oral Liquid or Extended-Release Tablet.

Dosing and Frequency

Formulation Type Standard Adult Dose Dosing Frequency Maximum Dose (24 Hours)
Immediate-Release (IR) 10 mL (liquid) Every 4 hours 6 doses
Extended-Release (ER) 1 tablet Every 12 hours 2 tablets

The total 24-hour intake of Dextromethorphan must not exceed 120 mg and Guaifenesin must not exceed 2400 mg. The course is intended for short-term treatment only and should generally not exceed seven consecutive days.

Administration Conditions

Standard instructions include taking D-Coate without regard to the timing of meals. For liquid formulations, the dose must be measured precisely using a calibrated device provided with the product, not a household spoon. Extended-release tablets must be swallowed whole with a full glass of water; they must not be crushed, chewed, or broken, as this would compromise the release mechanism. If a dose is missed, the next scheduled dose should be taken when due, and the dose should not be doubled to compensate.

Population-Specific Use

Labeling includes specific age restrictions, stating that the product is contraindicated in children under 4 years of age. Furthermore, some product labels advise Do Not Use in children under 12 years without explicit consultation with a healthcare professional.

Recent Clinical Evidence

Research evidence / Overview of studies for D-Coate


1. Evidence for Symptomatic Relief of Acute Cough

This section summarizes the available evidence for the antitussive component (Dextromethorphan), which was studied for its effects on the cough reflex. Research has primarily focused on adults and adolescents experiencing an acute cough associated with the common cold or other upper respiratory tract infections.

Studies explored short-term symptom changes, often using Randomized Controlled Trials (RCTs). These trials were designed to measure whether the single ingredient or the combination was associated with changes in cough frequency and cough severity, often using patient-reported outcomes describing perceived discomfort. The antitussive agent's function is established by regulatory monographs, drawing on the collective body of research.


2. Evidence for Management of Chest Congestion and Mucus

This section outlines the research available for the expectorant components (Guaifenesin and Terpin), which was evaluated in trials exploring the physical discomfort related to chest congestion and mucus production. Studies monitored outcomes linked to mucus thickness or viscosity and patient-reported scales for feeling of heaviness or phlegm in the chest. Findings describe patterns observed in the studies where patients reported subjective improvements in congestion. However, studies exploring the objective measures of mucus changes often demonstrated inconsistent results.

High-quality contemporary data for the Terpin component remains scarce in contemporary, high-quality peer-reviewed research, as its inclusion often relies on historical use and older regulatory contexts. Studies contribute to the broader evidence landscape, but they do not provide individual predictions of mucus clearance.


4. Evidence in Specific Age Groups and Populations

Research exploring short-term symptom changes was observed in adults and adolescents (typically over 12 years old). However, data for certain groups remain insufficient. For instance, evidence for the use of D-Coate's components in children is generally limited, and findings were mixed in the available pediatric research. Similarly, comparative evidence is lacking for patients with specific comorbid conditions or diseases characterized by functional limitations.

Key Studies & References

  1. Dextromethorphan Hydrobromide and Guaifenesin Oral Solution Drug Label
  2. Over-the-Counter Drugs Containing Guaifenesin; Final Rule
  3. Guaifenesin: A systematic review of clinical efficacy, safety, and pharmacology

Frequently Asked Questions (FAQ)

Common questions about D-Coate (FAQ)


Q: Is it normal to feel [general symptom] when starting D-Coate?

According to official product information, commonly reported side effects for the ingredients in D-Coate include dizziness, drowsiness, nausea, and vomiting. If these effects are experienced, they are generally noted to involve the nervous or gastrointestinal systems. If any effects are severe or do not go away, individuals may wish to consult a healthcare professional.


Q: Can D-Coate interact with common over-the-counter pain relievers?

Official guidance often recommends checking the active ingredients of all products to avoid accidental overdose from taking multiple medicines containing the same component. While no major interaction is typically noted between D-Coate's ingredients and common single-ingredient pain relievers like acetaminophen or ibuprofen, it is important to check labels and review combination use with a healthcare professional.


Q: Is there a warning about driving or operating machinery while taking D-Coate?

Regulatory warnings indicate that D-Coate can cause central nervous system effects such as drowsiness and dizziness. Because of these known effects, official information indicates that caution is necessary when performing tasks that require complete mental alertness and motor coordination, such as driving or operating heavy machinery.


Q: Do studies suggest D-Coate works better for certain groups of people?

Clinical evidence for D-Coate is typically observed and established in adults and adolescents aged 12 and older. The evidence available is generally insufficient to specifically establish or compare effectiveness for restricted groups, such as younger children or patients with underlying long-term health conditions.


Q: What are some common reasons a doctor might tell someone not to take D-Coate?

The most absolute restriction listed in regulatory documents is use with, or within 14 days of stopping, certain antidepressant medicines known as Monoamine Oxidase Inhibitors (MAOIs). Other listed reasons for restriction include a known allergy to the ingredients, the presence of a chronic cough (such as with asthma), or a cough accompanied by excessive mucus.


Q: Does D-Coate expire, and what does the expiration date mean?

D-Coate, like all regulated medicines, is required to have an expiration date on its packaging. According to official guidelines, this date signifies the specific period during which the manufacturer guarantees the product will retain its full strength and safety when stored exactly as labeled.


Q: If D-Coate doesn't seem to be working, what is the usual next step described in treatment guides?

Official labeling advises that use should be discontinued if a person's cough lasts for more than seven days, comes back, or is accompanied by serious symptoms such as a fever, rash, or persistent headache. In any of these situations, consultation with a healthcare professional is indicated.


Q: What does the term 'contraindication' mean in relation to D-Coate?

A contraindication is a key regulatory term meaning that the medicine is absolutely prohibited for use in a specific situation. This restriction exists because the risk of harm in that situation significantly outweighs any potential benefit, such as when D-Coate is used with certain interacting drugs like MAOIs.


Q: What is the typical time frame to see the full therapeutic effects of D-Coate?

D-Coate is approved for short-term symptomatic relief of acute cough and congestion. The entire recommended maximum duration of use is generally limited to seven consecutive days, and improvement in symptoms should be expected within this period according to official use guidelines.


Q: How common is it for D-Coate to be taken with other prescription medicines?

While regulatory sources do not provide statistics on how frequently co-administration occurs, the official label lists several major classes of prescription medicines that require either prohibition or caution with D-Coate. This indicates that potential interactions are a significant and common safety consideration in clinical practice.


Q: How is D-Coate's effectiveness generally measured in clinical practice?

In clinical practice settings, the effectiveness of D-Coate is generally monitored through patient-reported outcomes. This includes tracking self-reported changes in the frequency and severity of the cough, the perceived ease of breathing, and the amount of mucus expelled over the short course of treatment.


Q: Is D-Coate known to be habit-forming or addictive?

D-Coate's ingredients, Dextromethorphan and Guaifenesin, are typically not classified as federally controlled substances when the product is used as directed. However, regulatory documents note that the Dextromethorphan component does have potential for misuse when taken in high doses.


Q: Does D-Coate affect blood pressure or heart rate?

The active ingredients, Dextromethorphan and Guaifenesin, are generally not noted to increase blood pressure or heart rate at recommended doses.


Q: What should be done if someone accidentally takes too much D-Coate?

Official drug information and regulatory documents advise that in the event of an overdose or suspicion of one, contacting their local Poison Control Center is necessary. Seeking emergency medical help is consistently indicated in official documents.


Q: Is D-Coate a federally controlled substance?

No, D-Coate is an over-the-counter (OTC) medicine in most jurisdictions and is not classified as a federally controlled substance under the US Controlled Substances Act.


Q: What general cautions are listed for D-Coate and alcohol consumption?

Official information advises to avoid or significantly limit the consumption of alcohol while taking D-Coate. This caution is based on the fact that alcohol may increase the risk of central nervous system (CNS) side effects, such as heightened drowsiness and impaired coordination.


Q: Are there any known interactions between D-Coate and herbal products?

Yes, some regulatory-associated sources specifically warn about the combination of Dextromethorphan (an active ingredient in D-Coate) and the herbal product St. John's wort. This combination is noted to potentially increase the risk of a serious adverse reaction known as Serotonin Syndrome.


Q: Is D-Coate typically a prescription-only medicine?

In most major jurisdictions, D-Coate, which is a Dextromethorphan/Guaifenesin combination product, is classified as an Over-the-Counter (OTC) medicine. This means it is generally available for purchase without the need for a medical prescription.

How should D-Coate be stored and disposed of?

How to Store and Dispose of D-Coate?

Storage Requirement Official Guideline
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze liquid forms.
Protection Keep the medicine out of the sight and reach of children. Protect from light and excess moisture.
Container Keep D-Coate in its original container and ensure the container is tightly closed.

The medicine must be kept within the specified temperature range and protected from environmental factors to maintain its integrity. Disposal of unused or expired D-Coate should prioritize the use of an official drug take-back program. The product must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of D-Coate found in:

A-Z Index: